Prompt and Sustained Suppression of Intraocular Inflammation with Adalimumab in Pediatric Patients with Non-Infectious Uveitis Resistant to Traditional Managements: A 6-Month Follow-Up Research

To assess the efficacy of adalimumab (ADA) on visual acuity (VA), ocular inflammation, vitreous haze and central macular thickness (CMT) in pediatric refractory non-infectious uveitis. Thirty-one eyes of 16 pediatric patients with uveitis of various etiologies were treated with ADA. VA, intraocular...

Full description

Saved in:
Bibliographic Details
Published in:Ocular immunology and inflammation 2023-12, Vol.ahead-of-print (ahead-of-print), p.1-5
Main Authors: Sonmez, Hatice Kubra, Evereklioglu, Cem, Gulmez Sevim, Duygu
Format: Article
Language:English
Subjects:
Adalimumab
Adalimumab - therapeutic use
Behçet's disease
Child
Follow-Up Studies
Humans
Inflammation - complications
Inflammation - drug therapy
intraocular inflammation
juvenile idiopathic arthritis
Retrospective Studies
Treatment Outcome
uveitis
Uveitis - diagnosis
Uveitis - drug therapy
Uveitis - etiology
Vision Disorders
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To assess the efficacy of adalimumab (ADA) on visual acuity (VA), ocular inflammation, vitreous haze and central macular thickness (CMT) in pediatric refractory non-infectious uveitis. Thirty-one eyes of 16 pediatric patients with uveitis of various etiologies were treated with ADA. VA, intraocular active inflammatory cells, vitreous haze, and CMT were evaluated at the baseline and 2 nd , 4 th , 12 th , and 24 th weeks following ADA treatment. Twenty-three of 31 eyes had active and the remaining 8 eyes had inactive uveitis (with frequent relapse) before ADA therapy. VA (LogMAR) increased at 12 th week following ADA treatment (p
ISSN:0927-3948
1744-5078
DOI:10.1080/09273948.2022.2139274